Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm expects to ship product within 2-3 weeks, Cephalon tells “The Pink Sheet” DAILY.

You may also be interested in...



Eisai Signs Bendamustine Deal With Symbio In Singapore And Korea, Highlighting Asian Oncology Market Potential

Tokyo-based biotech start-up Symbio will grant exclusive development and marketing rights for non-Hodgkin's lymphoma drug bendamustine to Japan's fourth-largest drug maker Eisai in both Korea and Singapore

Cephalon Showcasing Treanda Use For Refractory Indolent NHL At ASH

Cephalon's oncology drug Treanda is getting attention at the 2008 American Society of Hematology annual meeting, where the company is starting to showcase its use in the newest indication - refractory indolent non-Hodgkins lymphoma

Cephalon Showcasing Treanda Use For Refractory Indolent NHL At ASH

Cephalon's oncology drug Treanda is getting attention at the 2008 American Society of Hematology annual meeting, where the company is starting to showcase its use in the newest indication - refractory indolent non-Hodgkins lymphoma

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel